黑料网

Abstract

Esomeprazole is a proton pump inhibitor commonly prescribed for the treatment of gastrointestinal disorders such as gastro esophageal reflux disease, peptic ulcers, and Zollinger-Ellison syndrome. Understanding the pharmacokinetics of esomeprazole is crucial for optimizing its therapeutic efficacy and minimizing potential adverse effects. After oral administration, esomeprazole is rapidly absorbed from the gastrointestinal tract, with a bioavailability of approximately 50-68% due to first-pass metabolism in the liver. The drug is extensively bound to plasma proteins, primarily albumin, and has a relatively high volume of distribution, indicating good tissue penetration. Esomeprazole is primarily metabolized in the liver by cytochrome P450 enzymes, namely CYP2C19 and CYP3A4, resulting in the formation of inactive metabolites.